Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This influenza nasal spray vaccine is a live attenuated influenza virus-vectored candidate developed by Xiamen Wan Tai (Beijing Wantai Biological Pharmacy). Designed for intranasal administration, the vaccine utilizes a live attenuated influenza virus platform to express specific influenza antigens. This approach is intended to stimulate both mucosal and systemic immune responses, mimicking natural infection to provide broad protection against influenza. The vaccine is currently in the preclinical stage of development, leveraging the same viral vector technology used in the company's approved COVID-19 nasal spray vaccine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza nasal spray vaccine (virus-vectored).